Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004184-12
    Sponsor's Protocol Code Number:DTX401-CL301
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-08-26
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-004184-12
    A.3Full title of the trial
    A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
    Estudio de Fase 3, Aleatorizado, Doble Ciego y Controlado con Placebo de la Transferencia del Gen de la Glucosa-6-fosfatasa Mediada por el Virus Adenoasociado de serotipo 8 en Pacientes con Glucogenosis de Tipo Ia
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    An Phase 3 clinical study comparing a vector transferring the gene for Glucose-6-Phosphatase with placebo in adults with Glycogen Storage Disease Type Ia.
    Un estudio clínico de fase 3 que compara un vector que transfiere el gen de la glucosa-6-fosfatasa con placebo en adultos con Glucogenosis de Tipo Ia
    A.4.1Sponsor's protocol code numberDTX401-CL301
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUltragenyx Pharmaceutical Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUltragenyx Pharmaceutical Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUltragenyx Pharmaceutical Inc.
    B.5.2Functional name of contact pointClinical Development
    B.5.3 Address:
    B.5.3.1Street Address840 Memorial Drive
    B.5.3.2Town/ cityCambridge
    B.5.3.3Post codeMA 02139
    B.5.3.4CountryUnited States
    B.5.4Telephone number+34900 834 223
    B.5.6E-mailRegistroEspanolDeEstudiosClinicos@druginfo.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/16/1771
    D.3 Description of the IMP
    D.3.1Product nameDTX401
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot available.
    D.3.9.2Current sponsor codeDTX401
    D.3.9.4EV Substance CodeSUB192511
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number7300000000000 to 90000000000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Yes
    D.3.11.3.5.1CAT classification and reference numberClassified as gene therapy medicinal product, EMA/506999/2016.
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Glycogen Storage Disease Type Ia (GSDIa).
    Glucogenosis Tipo Ia (GGIa)
    E.1.1.1Medical condition in easily understood language
    Inherited disorder causing decrease of glucose.
    Trastorno hereditario que provoca una disminución de la glucosa.
    E.1.1.2Therapeutic area Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10056911
    E.1.2Term Glycogen storage disease type IA
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    •To reduce or eliminate dependence on exogenous glucose replacement therapy to maintain euglycemia
    •To maintain or improve the quality of glucose control
    •Reducir o eliminar la dependencia del tratamiento de reposición con glucosa exógena para mantener la normoglucemia.
    •Mantener o mejorar la calidad del control de la glucosa.
    E.2.2Secondary objectives of the trial
    •To evaluate the effect of DTX401 on glucose control
    •To evaluate the effect of DTX401 on reducing the frequency of exogenous glucose replacement therapy
    •To evaluate the effect of DTX401 on subject experience of disease
    •To evaluate the safety of DTX401
    •Evaluar el efecto de DTX401 en el control de la glucosa
    •Evaluar el efecto de DTX401 en la reducción de la frecuencia del tratamiento de reposición con glucosa exógena.
    •Evaluar el efecto de DTX401 en la experiencia de la enfermedad del sujeto.
    •Evaluar la seguridad de DTX401.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male and female patients ≥ 8 years of age at time of informed consent or assent.
    2. Subject has a diagnosis of GSDIa confirmed by deficient enzymatic activity (on liver biopsy), or by molecular testing of G6PC gene revealing 2 pathogenic mutations. In the case where only a single pathogenic mutation is identified, clinical diagnosis is compatible with GSDIa and absence of characteristic features of GSDIb (ie, chronic neutropenia, inflammatory bowel disease).
    3. Subject is currently receiving a therapeutic regimen of cornstarch (or equivalent) and clinically stable as evidenced by no more than a 10% weekly change in cornstarch (or equivalent) regimen; no more than 15% variation in weekly average euglycemia (60-120 mg/dL) assessed by CGM and no hospitalization for hypoglycemia during the 4-week period preceding randomization and dosing.
    4. Subject is willing and able to comply with study procedures and requirements, including periodic inpatient hospitalization or admission in a research facility; CFC studies; frequent blood collection; wearing a CGM device for the duration of the study (and excluding the use of any non-study CGM or flash glucose device); performing capillary glucose measurements using a study-approved glucometer (and excluding the use of any other glucometer); completing an eDiary routinely throughout the study to track daily cornstarch, dietary intake, and reason for performing SMBG; and completing patient-reported questionnaires. If < 18 years (or as required by region), has a parent or legal guardian willing and able to assist with study requirements.
    5. From the period following informed consent through the duration of participation in the study, female subjects of childbearing potential and fertile male subjects must consent to use highly effective contraception as defined by the Food and Drug Administration (FDA) and Clinical Trial Facilitation Group Recommendations Related to Contraception and Pregnancy Testing in Clinical Trials (Version 1.1 dated 21 Sep 2020). Female subjects must agree not to become pregnant and male subjects must agree not father a child or donate sperm for at least 48 weeks after the last dose of IP if they decide to withdraw early from the study.
    6. Subject is willing and able to provide written informed consent after the study has been explained and before any study-related procedures are performed. If < 18 years (or as required by region), willing and able to provide written assent and have a parent or legal guardian willing and able to provide written informed consent after the study has been explained and before any study-related procedures are performed.
    1. Pacientes de ambos sexos de ≥8 años de edad en el momento del consentimiento o asentimiento informado.
    2. El sujeto tiene un diagnóstico de GGIa confirmado por una actividad enzimática deficiente (en una biopsia hepática) o por un análisis molecular del gen G6PC que revela 2 mutaciones patógenas. Si solo se identifica una única mutación patógena, el diagnóstico clínico es compatible con GGIa y ausencia de signos característicos de GGIb (es decir, neutropenia crónica, enfermedad inflamatoria intestinal).
    3. El sujeto está recibiendo actualmente una pauta terapéutica con almidón de maíz (o equivalente) y se encuentra clínicamente estable, según lo evidenciado por un cambio semanal no superior al 10 % de la pauta de almidón de maíz (o equivalente), por una variación semanal de la media no superior al 15 % en la normoglucemia (60 120 mg/dl) evaluada mediante MCG y por la ausencia de hospitalización por hipoglucemia durante el periodo de 4 semanas anterior a la aleatorización y administración.
    4. El sujeto se muestra dispuesto y capaz de cumplir los procedimientos y requisitos del estudio, tales como hospitalización periódica o ingreso en un centro de investigación; estudios de PPAC; extracción frecuente de sangre; uso de un dispositivo de MCG durante todo el estudio (excluyendo el uso de cualquier MCG o dispositivo flash de glucosa no relacionado con el estudio); realización de mediciones de glucosa capilar con un glucómetro aprobado para el estudio (excluyendo el uso de cualquier otro glucómetro); cumplimentación de un diario electrónico para registrar diariamente el almidón de maíz, la ingesta alimentaria y el ACG de forma sistemática durante todo el estudio; y cumplimentación de cuestionarios comunicados por los pacientes.. En caso de ser menor de 18 años (o según lo exigido por la región), tiene un progenitor o tutor legal con disposición y capacidad para ayudar con los requisitos del estudio.
    5. Desde el periodo posterior al consentimiento informado y durante todo el estudio, las mujeres en edad fértil y los varones fértiles que participen en el estudio deberán otorgar su consentimiento para utilizar métodos anticonceptivos muy eficaces, según lo definido por la Administración de Alimentos y Medicamentos de EE. UU. (FDA) y las recomendaciones del grupo de facilitación de ensayos clínicos relativas a la anticoncepción y las pruebas de embarazo en ensayos clínicos (versión 1.1 de 21 de septiembre de 2020). Las mujeres deberán comprometerse a no quedarse embarazadas y los varones deberán comprometerse a no engendrar hijos ni donar semen durante al menos 48 semanas después de la última dosis del PEI si deciden retirarse del estudio antes de tiempo.
    6. El sujeto se muestra dispuesto y capaz de firmar el consentimiento informado por escrito una vez explicado el estudio y antes de someterse a cualquier procedimiento relacionado con el estudio. Si tiene menos de 18 años (o según lo exigido por la región), se muestra dispuesto y capaz de otorgar su asentimiento por escrito y tiene un progenitor o tutor legal con disposición y capacidad para otorgar su consentimiento informado por escrito después de que se le haya explicado el estudio y antes de realizar ningún procedimiento relacionado con este.
    E.4Principal exclusion criteria
    1. Detectable pre-existing antibodies to the AAV8 capsid.
    2. History of liver transplant, including hepatocyte cell therapy/transplant.
    3. History of liver disease as evidenced by any of the following: portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, or a liver biopsy with evidence of stage III fibrosis.
    4. Presence of liver adenoma > 5 cm in size or presence of liver adenoma > 3 cm and ≤ 5 cm in size with a documented annual growth rate of ≥ 0.5 cm per year.
    5. Significant hepatic inflammation or cirrhosis as evidenced by imaging or any of the following laboratory abnormalities:
    − ALT or aspartate aminotransferase > 2.5 × the ULN
    − Total bilirubin > 2.0 × ULN (except if patient has documented Gilbert’s syndrome)
    − Alkaline phosphatase > 2.5 × ULN
    6.Non-fasting triglycerides ≥ 1000 mg/dL. For the purposes of this study, non-fasting refers to the longest fasting period that each individual subject is able to tolerate. Depending on the meal and cornstarch schedule, the blood draw could occur in the morning before breakfast or before the first dose of cornstarch.
    7. Presence or history of hepatitis B virus infection, hepatitis C virus infection, or both.
    8. Human immunodeficiency virus infection AND any of the following: CD4+ cell count < 350 cells/mm3, change in antiretroviral therapy regimen within 6 months before baseline, or plasma viral load > 200 copies/mL on 2 separate occasions as measured by polymerase chain reaction.
    9. Presence or history of any disease or condition that, in the Investigator’s opinion, would interfere with the subject’s safety or ability to participate in the study or would significantly affect interpretation of study results. This includes any intercurrent febrile or nonfebrile illness including common viral infections, epidemic influenza, and coronavirus disease 2019 (COVID-19) until full clinical recovery.
    10. Female subjects of childbearing potential who have a positive serum pregnancy test at screening or a positive urine pregnancy test at baseline or who are unwilling to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have not experienced menarche, are postmenopausal (defined as having no menses for at least 12 months without an alternative medical cause), or are permanently sterile due to having total hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
    11. Pregnant, breastfeeding, or planning to become pregnant (self or partner) at any time during the study.
    12. Presence or history of any hypersensitivity to the excipients of DTX401 or placebo or to prednisolone, or inability to swallow capsules that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.
    13. Current or previous participation in another gene transfer study.
    14. Use of any IP or investigational medical device within 3 months preceding screening or planning to use at any time during the study.
    15. History of illicit drug use within 60 days prior to screening or positive results from a 9-panel urine drug screen during the Screening Period completed at 2 time points at least 4 weeks apart. Positive results that are due to a prescribed medication may be allowed if not impacting glycemic control and liver function and after agreement with the Sponsor. For the purposes of this protocol, the use of recreational cannabis products is not allowed, even if legal in the region where the patient lives.
    1. Anticuerpos preexistentes detectables frente a la cápside del AAV8.
    2. Antecedentes de trasplante de hígado, incluido el tratamiento/trasplante de hepatocitos.
    3. Antecedentes de hepatopatía, manifestada por alguno de los siguientes: hipertensión portal, ascitis, esplenomegalia, varices esofágicas, encefalopatía hepática o una biopsia de hígado con indicios de fibrosis en estadio III.
    4. Presencia de adenoma hepático con un tamaño >5 cm o presencia de adenoma hepático con un tamaño >3 cm y ≤5 cm con una tasa de crecimiento anual documentada ≥0,5 cm al año.
    5. Inflamación hepática o cirrosis significativas demostradas mediante estudios de imagen o cualquiera de las siguientes anomalías analíticas:
     ALT o aspartato aminotransferasa >2,5 veces el LSN.
     Bilirrubina total >2,0 veces el LSN (excepto si el paciente tiene un síndrome de Gilbert documentado).
     Fosfatasa alcalina >2,5 veces el LSN.
    Durante el periodo de selección se podrán repetir las pruebas de función hepática a criterio del investigador.
    6. Triglicéridos sin ayuno ≥1000 mg/dl. En este estudio, «sin ayuno» se refiere al periodo de ayuno más largo que puede tolerar cada sujeto. Dependiendo del calendario de comidas y almidón de maíz, la extracción de sangre podrá realizarse por la mañana antes del desayuno o antes de la primera dosis de almidón de maíz.
    Durante el periodo de selección se podrán repetir las pruebas de triglicéridos a criterio del investigador.
    7. Presencia o antecedentes de infección por el virus de la hepatitis B, infección por el virus de la hepatitis C o ambas.
    8. Infección por el virus de la inmunodeficiencia humana Y cualquiera de los siguientes: Recuento de linfocitos CD4+ <350 células/mm3, variación de pauta de tratamiento antirretroviral en los 6 meses anteriores al momento basal o viremia en plasma >200 copias/ml documentada en dos ocasiones distintas mediante reacción en cadena de la polimerasa.
    9. Presencia o antecedentes de cualquier enfermedad o trastorno que, en opinión del investigador, pueda interferir en la seguridad o la capacidad del sujeto para participar en el estudio o afectar significativamente a la interpretación de los resultados del estudio. Esto incluye cualquier enfermedad febril o no febril intercurrente, como infecciones virales comunes, gripe epidémica y enfermedad coronavírica de 2019 (COVID-19) hasta la recuperación clínica completa.
    10. Mujeres en edad fértil que tengan una prueba de embarazo en suero positiva en la selección o una prueba de embarazo en orina positiva en el momento basal o que no estén dispuestas a hacerse pruebas de embarazo adicionales durante el estudio. Las mujeres que no se consideran en edad fértil son aquellas que no han experimentado la menarquia, que son posmenopáusicas (es decir, que no han tenido menstruación durante al menos 12 meses sin una causa médica alternativa) o que se han sometido a esterilización permanente por histerectomía total, salpingectomía bilateral u ovariectomía bilateral.
    11. Embarazo, lactancia o intención de quedarse embarazada (la propia participante o la pareja del participante) en cualquier momento durante el estudio.
    12. Presencia o antecedentes de hipersensibilidad a los excipientes de DTX401 o del placebo o a la prednisolona, o incapacidad para tragar cápsulas que, en opinión del investigador, aumente el riesgo de efectos adversos para el sujeto.
    13. Participación actual o previa en otro estudio de transferencia génica.
    14. Uso de cualquier PEI o producto sanitario experimental en los 3 meses previos a la selección o previsión de utilizarlo en cualquier momento durante el estudio.
    15. Antecedentes de consumo de drogas en los 60 días previos a la selección o resultados positivos en un análisis toxicológico en orina de 9 determinaciones durante el periodo de selección, realizado en 2 momentos con 4 semanas de diferencia como mínimo. Podrán permitirse resultados positivos debidos a un medicamento prescrito siempre que no afecten al control de la glucemia ni a la función hepática y previo acuerdo con el promotor. En este protocolo no se permite el uso de productos recreativos de cannabis, aunque sea legal en la región donde vive el paciente.
    E.5 End points
    E.5.1Primary end point(s)
    1. Percent change from Baseline to Week 48 in daily cornstarch intake for the DTX401 Group compared with the Placebo Group for superiority.
    2. Change from Baseline to Week 48 in the percentage of time spent in normal glucose control (60 to 120 mg/dL [3.3 to 6.7 mmol/L]) for the DTX401 Group compared with the Placebo Group, as measured by CGM for noninferiority.
    1. Variación porcentual entre el momento basal y la semana 48 de la ingesta diaria de almidón de maíz en el grupo de DTX401 en comparación con el grupo de placebo para establecer la superioridad.
    2. Variación entre el momento basal y la semana 48 del porcentaje de tiempo pasado con un control normal de la glucosa (de 60 a 120 mg/dl [de 3,3 a 6,7 mmol/l]) en el grupo de DTX401 en comparación con el grupo de placebo, determinado mediante MCG para establecer la no inferioridad.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. Baseline, week 12, week 24, week 30, week 36, week 42, week 48.
    2. Baseline, day 1 to 12, week 12, week 24, week 30, week 36, week 48.
    1. Momento basal, semana 12, semana 24, semana 30, semana 36, ​​semana 42, semana 48.
    2. Momento basal, día 1 a 12, semana 12, semana 24, semana 30, semana 36, ​​semana 48.
    E.5.2Secondary end point(s)
    1. Change from Baseline to Week 48 in time to hypoglycemia (< 54 mg/dL [3.0 mmol/L]) during a CFC
    2. Change from Baseline to Week 48 in percentage of time spent in normal glucose control (60 to 120 mg/dL [3.3 to 6.7 mmol/L]), as measured by CGM for superiority.
    3. Change from Baseline to Week 48 in number of total daily doses of cornstarch.
    4. Change from Baseline to Week 48 in the GSD FAD Signs and Symptoms Scale for the DTX401 Group compared with the Placebo Group.
    5. Incidence, severity, and relationship to investigational product of TEAEs, TEAEs of special interest, serious TEAEs, related TEAEs, discontinuations from study or investigational product due to AEs, and fatal AEs.
    6. Clinically relevant changes in standard chemistry, hematology, urinalysis panels, physical exams, and vital signs.
    1. Variación entre el momento basal y la semana 48 en el tiempo transcurrido hasta la hipoglucemia (<54 mg/dl [3,0 mmol/l]) durante una PPAC.
    2. Variación entre el momento basal y la semana 48 del porcentaje de tiempo pasado con un control normal de la glucosa (de 60 a 120 mg/dl [de 3,3 a 6,7 mmol/l]) determinado mediante MCG para establecer la superioridad.
    3. Variación entre el momento basal y la semana 48 del número total de dosis diarias de almidón de maíz
    4. Variación entre el momento basal y la semana 48 de la Escala de signos y síntomas del DEF-GG en el grupo de DTX401 en comparación con el grupo de placebo.
    5. Incidencia, intensidad y relación con el producto en investigación de los AAST, AAST de interés especial, AAST graves, AAST relacionados, retiradas del estudio o del producto en investigación por AA y AA mortales
    6. Variaciones de interés clínico de los parámetros habituales de bioquímica, hematología, análisis de orina, exploraciones físicas y constantes vitales
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Baseline, week 12, week 24, week 36, week 48.
    2. Baseline, day 1 to 12, week 12, week 24, week 30, week 36, week 48.
    3. Baseline, week 12, week 24, week 30, week 36, week 42, week 48.
    4. Baseline, week 12, week 24, week 30, week 36, week 42, week 48.
    5. From the time the subject signs the Informed Consent Form (ICF) and up to 30 days after the End of Study Visit or Early Withdrawal/Termination Visit.
    6. From the time the subject signs the ICF and up to 30 days after the End of Study Visit or Early Withdrawal/Termination Visit
    1. Momento basal, semana 12, semana 24, semana 36, ​​semana 48.
    2. Momento basal, día 1 a 12, semana 12, semana 24, semana 30, semana 36, ​​semana 48.
    3. Momento basal, semana 12, semana 24, semana 30, semana 36, ​​semana 42, semana 48.
    4. Momento basal, semana 12, semana 24, semana 30, semana 36, ​​semana 42, semana 48.
    5. Desde el momento en que el sujeto firma el Formulario de consentimiento informado (ICF) y hasta 30 días después de la visita de fin de estudio o visita de retiro anticipado / última visita.
    6. Desde el momento en que el sujeto firma el ICF y hasta 30 días después de la visita de fin de estudio o visita de retiro anticipado / última visita.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    Canada
    Japan
    United States
    Denmark
    France
    Germany
    Italy
    Netherlands
    Portugal
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The date of the Week 96 Visit (or Early Withdrawal Visit, if applicable) for the last participant enrolled in the study.
    La fecha de la visita de la semana 96 (o visita de retiro anticipado, si corresponde) del último participante reclutado en el estudio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 10
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 5
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 5
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 36
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 4
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state4
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 23
    F.4.2.2In the whole clinical trial 50
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After patients have ended their participation in the trial, they will be treated according to the normal standard of care. Upon completion of this study, all subjects who receive DTX401 are expected to enroll in a long-term follow-up study to evaluate safety and effectiveness of DTX401 via the DMP for at least 10 years after DTX401 administration. The DMP for GSDIa will be conducted under a separate protocol.
    Una vez que los pacientes hayan terminado su participación en el ensayo, serán tratados de acuerdo con el estándar de atención habitual. Una vez finalizado este estudio, se espera que todos los sujetos que reciban DTX401 sean reclutados en un estudio de seguimiento a largo plazo para evaluar la seguridad y eficacia de DTX401 a través del DMP durante al menos 10 años después de su administración. El DMP para GGIa se llevará a cabo bajo un protocolo separado.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-11-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-10-04
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 10:37:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA